Exemestane: A Tracking Guide for the Steroidal AI

Exemestane (Aromasin) is a steroidal aromatase inhibitor. Unlike non-steroidal AIs such as anastrozole, it binds the aromatase enzyme irreversibly - a so-called suicide inhibitor - so its effect persists until the body makes new enzyme. It is a breast-cancer drug used off-label by men to control estrogen on testosterone or steroids.

This is an educational tracking guide. Exemestane is prescription-only. Like any AI, the central risk is over-suppressing estrogen, with all the harm that causes.

What it does

• Irreversibly inhibits aromatase, lowering estradiol
• Because the binding is permanent, there is less estrogen "rebound" than with non-steroidal AIs when you stop
• Has mild androgenic and possibly favorable lipid characteristics that some prefer over non-steroidal AIs
• Still capable of crashing estrogen if over-dosed

How it differs from anastrozole

• Irreversible vs reversible binding (different rebound behaviour)
• Sometimes reported as kinder to lipids
• Still requires the same careful, estradiol-guided dosing

What to track daily

• Dose, timing
• Libido and erectile function
• Joint comfort and dryness
• Mood and energy
• Water retention and nipple symptoms

What to track weekly

• Well-being and libido trend
• Joint comfort
• Blood pressure and weight

Bloodwork worth doing

• Baseline: sensitive estradiol, total and free testosterone, lipids
• 1-2 weeks after any dose change: re-check sensitive estradiol
• Periodically: lipids; bone health for long-term use
• Again, target a healthy estradiol range, not the floor

Realistic expectations

• Similar net effect to other AIs with somewhat different kinetics
• Over-suppression risk is the same: joints, libido, mood, bone
• Still a titrate-carefully drug

Common mistakes

• Assuming "steroidal" means it cannot crash estrogen - it can
• Dosing without measuring sensitive estradiol
• Chasing the lowest estrogen
• Ignoring low-estrogen symptoms

A tracking template

• Pre: baseline sensitive estradiol, testosterone, lipids
• On: daily symptom logs, re-test sensitive estradiol 1-2 weeks after changes
• Long-term: lipids and bone health

Safety notes

Same low-estrogen risks as other AIs: bone density loss, joint pain, low libido, poor mood. Irreversible binding means its effect lingers after the last dose - account for that when titrating. Prescription-only; manage under a physician with the sensitive estradiol assay.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.